CoChat

Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization

Open access
Oyama, Kazuma, Furtado, Remo H.M., Fagundes, Antonio, Zelniker, Thomas A., Tang, Minao, Kuder, Julia, Murphy, Sabina A., Hamer, Andrew, Wang, Huei, Keech, Anthony C., Giugliano, Robert P., Sabatine, Marc S., Bergmark, Brian A. · 2021 · Journal of the American College of Cardiology
Cited by 41

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors induce plaque regression and reduce the risk of coronary revascularization overall. OBJECTIVES To evaluate the ability of PCSK9 inhibitors to reduce the risk of complex coronary atherosclerosis requiring revascularization. METHODS FOURIER was a randomized trial of the PCSK9 inhibitor evolocumab vs. placebo in 27,564 patients with stable atherosclerosis on statin therapy followed for a median of 2.2 years. Clinical documentation of revascularization events was blindly reviewed to assess coronary anatomy and procedural characteristics. Complex revascularization was the composite of complex percutaneous coronary intervention (PCI) (as per previous analyses, >1 of: multivessel PCI, ≥3 stents, ≥3 lesions treated, bifurcation PCI, or total stent length >60 mm) or coronary artery bypass grafting surgery (CABG). RESULTS 1,724 patients underwent coronary revascularization, including 1482 who underwent PCI, 296 who underwent CABG, and 54 both. Complex revascularization was performed in 632 (37%) patients. Evolocumab reduced the risk of any coronary revascularization by 22% (HR 0.78 [0.71-0.86]; P<0.001), simple PCI by 22% (HR 0.78, [0.70-0.88]; P<0.001), complex PCI by 33% (HR 0.67 [0.54-0.84]; P<0.001), CABG by 24% (HR 0.76 [0.60-0.96]; P=0.019), and complex revascularization by 29% (HR 0.71 [0.61-0.84]; P<0.001). The magnitude of the risk reduction with evolocumab in complex revascularization tended to increase over time (20%, 36%, and 41% risk reductions in 1st, 2nd and beyond 2nd year). CONCLUSIONS Adding evolocumab to statin therapy significantly reduced the risk of developing complex coronary disease requiring revascularization, including complex PCI and CABG individually.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2020.11.011

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 41

Metadata

Authors
Oyama, K., Furtado, R. H. M., Fagundes, A., Zelniker, T. A., Tang, M., Kuder, J., Murphy, S. A., Hamer, A., Wang, H., Keech, A. C., Giugliano, R. P., Sabatine, M. S., & Bergmark, B. A.
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2021-01
Volume
77
Issue
3
Pages
259-267
ISSN
0735-1097 (ISSN-L)
OpenAlex
W3101397443
Cited by
41
References
8
FWCI
5.34
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. https://app.cochat.ai/papers/10.1016/j.jacc.2020.11.011
The paper
Oyama, K., Furtado, R. H. M., Fagundes, A., Zelniker, T. A., Tang, M., Kuder, J., Murphy, S. A., Hamer, A., Wang, H., Keech, A. C., Giugliano, R. P., Sabatine, M. S., & Bergmark, B. A. (2021). Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2020.11.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.